Drugs / Extracellular vesicles
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06937528 | Jan 2024 → Jan 2026 overdue | osteoarthritis, knee | University of Jordan | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06002841 | Feb 2024 → Jun 2025 | acute respiratory distress syndrome, pneumonia, severe acute respiratory syndrome | D'Or Institute for Research and Education | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Extracellular vesicles | “intravenous treatment with extracellular vesicles” NCT06002841 ↗ |
| Route | Intravenous | “intravenous administration of extracellular vesicles obtained from mesenchymal cells” NCT06002841 ↗ |